Millipore Sigma Vibrant Logo

616464 InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem

概述

Replacement Information

重要规格表

CAS #Empirical Formula
301836-41-9C₂₂H₁₆N₄O₃ • 2H₂O

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
616464-5MGCN
正在查询供货情况......
目前缺货
目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余:另行通知
      其余:另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      玻璃瓶 5 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      Request Pricing
      Description
      OverviewA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220). The solid form of this compound (Cat. No. 616461) is also available.
      Catalogue Number616464
      Brand Family Calbiochem®
      References
      ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
      Product Information
      CAS number301836-41-9
      FormLiquid
      FormulationA 100 mM (5 mg/119 µl) solution of SB431542 (Cat. No. 616461) in DMSO.
      Hill FormulaC₂₂H₁₆N₄O₃ • 2H₂O
      Chemical formulaC₂₂H₁₆N₄O₃ • 2H₂O
      Hygroscopic Hygroscopic
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationInSolution™ TGF-β RI Kinase Inhibitor VI, SB431542, CAS 301836-41-9, is a 100 mM solution in DMSO.A cell-permeable, selective inhibitor of SMAD2 phosphorylation (greater than 90% inhibition at 10 µM).
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/38

      Irritating to eyes and skin.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      616464-5MGCN 04055977185942

      Documentation

      InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem 分析证书

      标题批号
      616464

      参考

      参考信息概述
      Ikushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision01-February-2012 RFH
      DescriptionA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220).
      FormLiquid
      FormulationA 100 mM (5 mg/119 µl) solution of SB431542 (Cat. No. 616461) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number301836-41-9
      Chemical formulaC₂₂H₁₆N₄O₃ • 2H₂O
      Structure formulaStructure formula
      Purity≥97% by HPLC
      Storage Protect from light
      -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Irritant
      ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.